The DNA stock price malaise is mostly due to Avastin sales growth not living up to initial expectations. Many analysts were hoping for 5-10B peak sales, but its struggled to top 3B. Rutuxan and Herceptin have done better than expected, but DNA does not have much of a late-stage pipeline...